DeepMed Research

SWOG

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1956-01-01

Employees: 101

Market Cap: -

Website: http://www.swog.org

Clinical Trials

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

Phase 3

Terminated

Conditions: Bladder Cancer

Interventions: Procedure: surgical procedure
Drug: cephalexin
Drug: Ciprofloxacin

First Posted Date: 2004-04-14

Last Posted Date: 2012-03-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 114

Registration Number: NCT00003824

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States

and more 87 locations

S9923 R115777 in Treating Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: R115777

First Posted Date: 2004-04-12

Last Posted Date: 2012-06-14

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 62

Registration Number: NCT00005833

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 9 locations

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

Phase 2

Terminated

Conditions: Melanoma (Skin)
Metastatic Cancer

First Posted Date: 2004-04-12

Last Posted Date: 2013-01-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 2

Registration Number: NCT00003911

Locations: 🇺🇸
Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States
🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States

and more 83 locations

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-12

Last Posted Date: 2013-02-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 88

Registration Number: NCT00004137

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States

and more 82 locations

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: etoposide
Drug: tirapazamine
Radiation: radiation therapy

First Posted Date: 2004-04-02

Last Posted Date: 2012-10-04

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 30

Registration Number: NCT00006487

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 84 locations

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2004-03-17

Last Posted Date: 2013-04-10

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 7

Registration Number: NCT00006708

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States

and more 82 locations

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: dexamethasone
Drug: etoposide
Drug: thalidomide

First Posted Date: 2004-03-16

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 19

Registration Number: NCT00005834

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 90 locations

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Leukemia

Interventions: Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: methotrexate
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2004-03-16

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 240

Registration Number: NCT00005866

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
CCOP - Virginia Mason Research Center, Seattle, Washington, United States
🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

and more 63 locations

S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Procedure: laser surgery
Radiation: radiation therapy

First Posted Date: 2004-03-01

Last Posted Date: 2012-06-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 42

Registration Number: NCT00003040

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 9 locations

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Phase 3

Completed

Conditions: Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: paclitaxel

First Posted Date: 2004-02-20

Last Posted Date: 2014-10-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 308

Registration Number: NCT00003120

Locations: 🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 90 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy